Logo

Regulus Grosses a Total of $80.9M from Recent Transactions

Nov 08, 2012
Premium

Regulus Therapeutics this week announced that it grossed a total of $80.9 million from its recent initial public offering on the Nasdaq and other transactions.

The company went public in early October, floating its shares at $4 apiece, down from an originally expected $10 to $12 a share (GSN 10/4/2012). The total gross proceeds include $50.9 million from the public sale of common stock, $25 million from the sale of stock in a private placement with partner AstraZeneca, and $5 million from the sale of a convertible note in August to collaborator Biogen Idec.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
RNAi
miRNA
Regulus
AstraZeneca
financing
Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.